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Abstract: Receiving an opioid prescription during childhood increases the risk of hazardous prescription opioid (PO) use during emerging adulthood. Instruction on how to safely use POs plays
an essential role in pediatric patients’ capacity to utilize as well as to discontinue POs appropriately.
This study aimed to evaluate pediatric PO label instructions provided to a large sample of pediatric
outpatients. Data were extracted from the electronic healthcare records system identifying pediatric
patients who received a PO between 2016 and 2019 from pediatric outpatient medical clinics were
affiliated with a northwestern United States medical center and children’s hospital. Pediatric patients
(n = 12,613) between 0–17 years old who received a PO during outpatient care were included. Patients
with chronic health conditions (e.g., cancer) or who received their PO from an inpatient medical setting were excluded. Patient demographics, medication instructions, associated diagnoses, and other
prescription information (e.g., name of medication, dose, and quantity dispensed) were examined
using automated text classification. Many label instructions did not include any indication/reason
for use (20.8%). Virtually none of the POs (>99%) included instructions for how to reduce/wean off
POs, contact information for questions about the POs, and/or instructions around how to dispose
of the POs. Efforts are needed to ensure that pediatric PO instructions contain essential elements to
improve comprehension of when and how to use POs for pediatric patients.
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1. Introduction
Prescription opioids (POs) given to children during the course of routine outpatient
treatment for pain can increase risk for hazardous PO use during young adulthood [1].
Childhood is an especially vulnerable period, as the use of POs before age 13 increases risk
for later opioid use disorders (OUD) compared with later exposure [2]. Even the receipt
of a PO for pain may unintentionally lead to pleasurable sensations of feeling “high” [3],
and PO prescriptions are associated with a 33% increased risk for later hazardous PO use
among children who would otherwise be at low risk for OUD (e.g., no history of substance
use) [1].
Many adolescents are first introduced to POs through legitimate prescriptions to treat
pain by medical providers [1,4]. No formal guidelines exist for PO prescribing for acute
pain in children. Although opioids are now used less in clinical practice where possible,
opioids are still necessary to control pain in some cases, particularly post-operatively [5].
The rates of adolescent PO use are high, with 7.2% and 14.3% of high school students
reporting current and lifetime PO use, respectively [6]. Additionally, the rates of PO-related
suicides in this age group continue to increase [7,8]. This is concerning given that medical
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providers tend to prescribe more POs than medically necessary for pediatric patients [9,10],
leaving 58–92% of pediatric POs unused and available for potential hazardous use [10,11].
Further, only 1 in 5 families are informed about how to safely dispose of their children’s
leftover POs [12].
Medication instructions play an essential role in parents0 management of pediatric
medications and represent a key modifiable target within the domain of “opioid stewardship.” Specifically, when instructions are vague, they can be misinterpreted, leading to
confusion and incorrect use of pediatric PO medications [13–15]. Awkward phrasing of
instructions (e.g., 1 mg/1 mL solution—give 0.8 mg every 3 h prn pain) can be difficult
to interpret, particularly for families who are not primary English speakers and/or who
have lower levels of health literacy [16,17]. While pediatric providers have been urged to
present instructions in a clear, concise, and unambiguous manner [14], these efforts have
not always been successful.
Adult studies show that high levels of instruction complexity, specifically related to
dosing, have been associated with greater confusion or error in medication use; medication labels with multistep instructions have been reported to be more difficult to use as
prescribed [18]. Prior studies have also found that dosing instructions with less complexity,
such as those using numerals (“1” vs. “one”) and simple medication descriptions (“pill”
vs. “tablet”), were preferred by adult patients [19]. “Take-Wait-Stop” labeling, which
simplifies text (e.g., replacing “do not exceed” with “do not take more than”) and separates
instructions more clearly into the number of pills to take, minimum interval between doses,
and maximum daily dose, reduced errors in adult PO medication use [20]. Specifying “time
periods” instead of “times per day” and specific times (e.g., take at bedtime) in place of
hourly intervals (e.g., take every 4–6 h) also enhanced adult comprehension in medication
use [21].
More data are needed to understand the nature of pediatric PO instructions for young
patients. Complicating these instructions, the vast majority of pediatric PO instructions
specify that medication is to be taken “as needed”, but many fail to include how, when, or
why to use and how, when, or why to discontinue use [22,23]. Additionally, while parents
may receive additional written discharge or after-visit instructions on paper or in electronic
communication, these often contain an overwhelming amount of text and are frequently
either misplaced and/or not kept with the medication [24]. This leaves parents with little
information about how to safely use and stop or taper pediatric PO use as their child’s pain
resolves. In this exploratory study, we examined label instructions for pediatric PO use
given during routine outpatient pain management. Specifically, we aimed to describe the
structure and content of pediatric PO instructions with a young sample. We also aimed to
determine whether the characteristics of the pediatric PO label instructions differed based
on the prescribing department and age of the pediatric patient. We hypothesized that
pediatric PO medication instructions would differ between surgical and medical specialties
due to different workflows and indications (painful condition vs. post-operative pain)
and between older and younger patients due to different provider perceptions of patient
autonomy and comprehension.
2. Methods
2.1. Procedures
Data were collected using the Research Data Warehouse (RDW), a service provided by
the Oregon Clinical and Translational Research Institute (OCTRI) at a northwest medical
school. The RDW provided a repository of data from the electronic medical records of
pediatric patients who were eligible for the study. Prescription information for children
ages 0 to 17 years who received a pediatric PO between 1 January 2016 and 31 December
2019 in the context of routine pediatric outpatient or ambulatory care met inclusion criteria
and was extracted from the RDW. Information related to patient demographics, type of PO,
dose, quantity dispensed, instructions provided on the prescription label, and associated
diagnoses were extracted. In order to capture pediatric POs given in outpatient settings
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POs given in outpatient settings for generally healthy children, patients with chronic
diseases (e.g., cystic fibrosis), patients with blood disorders or cancer/neoplasms, patients
with congenital disorders, those who received their pediatric PO through an inpatient
unit, and routes of administration other than oral were excluded. This investigation was
approved by the participating Institutional Review Board.
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Figure 1. Flowchart of pediatric prescription opioid (PO) instructions

An iterativeAnalysis
process was used to refine classification by identifying frequently repeated
2.3. Statistical
pediatric PO phrases not automatically classified in the preceding round and including
Analyses were performed in RStudio (Version 1.3.1093). Pediatric PO instructions
them in the algorithm for the subsequent round; an additional 5% of pediatric POs were
specifying a route of pediatric PO administration other than oral were excluded from
manually classified to verify the accuracy of automatic classification. Elements that were
analysis as these are less representative of the low complexity pediatric ambulatory care
not automatically classified in the preceding process were reviewed by two study team
population examined in this study. Frequency tables were developed for pediatric PO
members.
2.3. Statistical Analysis
Analyses were performed in RStudio (Version 1.3.1093). Pediatric PO instructions
specifying a route of pediatric PO administration other than oral were excluded from
analysis as these are less representative of the low complexity pediatric ambulatory care
population examined in this study. Frequency tables were developed for pediatric PO
instruction features posited to impact instruction clarity (e.g., specific dosing instructions,
maximum amount of medication to use per day, when to discontinue use), as well as
elements that occurred frequently during the iterative review of pediatric PO instructions
by study team members.

Children 2022, 9, 707

4 of 9

Frequency of each pediatric PO instruction element was compared between surgical
and non-surgical prescribing departments and between patients 13 and older and those
younger than 13 for those pediatric PO-instruction elements with significant variation
across pediatric PO prescriptions (>5% in each category). Chi-square tests were used for
these analyses. The odds ratios (ORs) and 95% confidence intervals (CIs) were calculated.
Surgical departments included those specialties recognized by the American College
of Surgeons: cardiothoracic surgery, colon and rectal surgery, general surgery, gynecology
and obstetrics, gynecologic oncology, neurological surgery, ophthalmic surgery, oral and
maxillofacial surgery, orthopedic surgery, otorhinolaryngology, pediatric surgery, plastic
and maxillofacial surgery, urology, and vascular surgery. All other departments were
classified as non-surgical. Non-surgical departments included outpatient general and
specialty clinics.
3. Results
3.1. Pediatric PO Patient Characteristics
A total of N = 11,213 pediatric PO patients ages 0–17 were identified. In line with this
metropolitan region, this sample was predominately non-Hispanic white (78%), Englishspeaking (91.1%), with a mean age of 11.1 (SD = 5.5), and N = 2032 (18.1%) Hispanic. In
addition, N = 6563 (58.5%) pediatric PO patients were male and N = 4650 (41.4%) were
female (see Table 1).
Table 1. Demographic information of study sample.
N (%)
Age
Gender
Female
Male
Race
non-Hispanic White
African American
Asian
Multiracial
Unknown or not reported
Ethnicity
Hispanic
Not Hispanic
Unknown or not reported
Primary language
English
Spanish
Other
Unknown

M (SD)
11.1 (5.5)

4650 (41.5%)
6563 (58.5%)
8747 (78.0%)
255 (2.3%)
355 (3.2%)
916 (8.2%)
940 (8.4%)
2032 (18.1%)
8625 (79.6%)
556 (5.0%)
10,219 (91.1%)
733 (6.5%)
169 (1.6%)
92 (0.8%)

3.2. Pediatric PO Instructions
Characteristics of pediatric PO instructions are listed in Table 2. Pediatric PO instructions given from a surgical department were significantly less likely to specify a discrete
amount of pediatric PO medication to take at one time (OR = 0.77, 95% CI [0.70, 0.85],
p < 0.001) and less likely to contain potentially confusing language (OR = 0.77, 95% CI
[0.70, 0.86], p < 0.001) than pediatric PO instructions from a non-surgical department were
(Table 3). Pediatric PO instructions from a surgical department were significantly more
likely to contain pediatric PO instructions to limit use (OR = 1.74, 95% CI [1.53, 1.97],
p < 0.001) and to specify the pain severity for which pediatric PO use was intended
(OR = 2.72, 95% CI [2.45, 3.02], p < 0.001) compared with pediatric PO instructions from a
non-surgical department.
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Table 2. Characteristics of pediatric prescription opioid (PO) instructions.
N (%) with element
Amount of pediatric PO to take
Discrete amount
Range
Amount as numeral
Amount as word
Frequency of pediatric PO to take
Specified frequency (every # hours)
Range (every # hours)
Specified frequency (# per day)
Range (# per day)
Route of pediatric PO administration
“As needed”
Pediatric PO indication specified
Severity of pain specified
Cause or location of pain specified
Additional pediatric PO instructions
Instructions to limit pediatric PO medication
Maximum dosing frequency
Maximum total amount
Maximum duration for pediatric PO use
Direction to use non-PO medication first
Instruction to minimize amount of pediatric PO
Instructions to wean pediatric PO
Weaning steps specified for pediatric PO
Potentially confusing phrasing

12,538 (99.4%)
10,664 (85.1%)
2474 (14.9%)
12,508 (99.8%)
30 (0.2%)
12,542 (99.4%)
12,365 (98.6%)
107 (0.9%)
69 (0.6%)
1 (0.0%)
12,534 (99.4%)
12,369 (98.1%)
9954 (78.9%)
9171 (92.1%)
235 (2.4%)
1534 (12.2%)
1161 (9.2%)
12 (1.0%)
477 (38.5%)
400 (34.5%)
304 (26.2%)
19 (1.6%)
142 (1.1%)
68 (47.9%)
2443 (19.4%)

Note. A total of 12,613 pediatric PO were analyzed.

Table 3. Results of analytic comparisons.
Patient Age

Prescribing Department
Characteristic
N (%) with
specified discrete
amount of
pediatric PO
N (%) with
instructions to
limit pediatric PO
N (%) with
severity of pain
specified
N (%) with
potentially
confusing
phrasing on
pediatric PO

Surgical

Non-Surgical

OR

95% CI

≥13 Years

<13 Years

OR

95% CI

2714 (76.6%)

7349 (81.0%)

0.77 ***

[0.70, 0.85]

3027 (70.3%)

7037 (84.7%)

2.35 ***

[2.15, 2.57]

454 (12.8%)

707 (7.8%)

1.74 ***

[1.53, 1.97]

354 (15.3%)

807 (9.7%)

1.20 ***

[1.05, 1.37]

3016 (85.1%)

6154 (67.9%)

2.72 ***

[2.45, 3.02]

3122 (72.4%)

6049 (72.8%)

1.02

[0.94, 1.11]

587 (16.6%)

1856 (20.5%)

0.77 ***

[0.70, 0.86]

945 (21.9%)

1498 (18.0%)

0.78 ***

[0.71, 0.86]

Note. OR = Odds ratios; CI = confidence interval. *** p < 0.001.

Pediatric PO instructions written for patients who were at least 13 years old were
significantly more likely to specify a discrete amount of pediatric PO to take at one time
(OR = 2.35, 95% CI [2.15, 2.57], p < 0.001) and more likely to contain pediatric PO instructions
to limit use (OR = 1.20, 95% CI [1.05, 1.37], p < 0.001) than pediatric PO instructions written
for patients under 13 years old (Table 3). Pediatric PO instructions written for patients who
were at least 13 years old were significantly less likely to contain potentially confusing
language (OR = 0.78, 95% CI [0.71, 0.86], p < 0.001) than pediatric PO instructions written
for patients under age 13. There was no significant difference in the frequency with which
pediatric PO instructions specified the pain severity for which the pediatric PO use was
intended between these age groups (OR = 1.02, 95% CI [0.94, 1.11], p > 0.05).
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4. Discussion
Our team was not able to identify any peer-reviewed published manuscripts that
utilized an empirical approach to examine pediatric PO medication label instructions
provided to young patients and their caregivers; thus, our study contributes novel empirical
information about label instructions provided for children receiving POs. In our study,
among the 12,613 pediatric PO label instructions given to young patients in the course of
routine outpatient treatment, a number of beneficial elements were identified. For example,
98.6% of the pediatric PO instructions specified a frequency with which the PO should be
taken (e.g., “every # hours”), and 99.4% included a route of administration. An amount
of pediatric PO to take per day was observed in 99.4% of instructions, and among them,
75.8% contained a specified discrete amount (e.g., “2 tablets”) rather than a range (e.g., “5
to 10 mL” or “1–2 pills”). Lastly, an indication (e.g., “for pain”) was specified in 78.9% of
the instructions, and among these, 89.7% included a severity level (e.g., for moderate or
severe pain). Indications were considered highly important for safe pediatric PO use by
supporting pediatric patients’ and their families’ understanding of the steps necessary to
take the pediatric PO in the manner that the provider intended [25].
Areas for pediatric PO improvement were also identified. For example, 21.1% pediatric
PO labels did not include an indication, and 14.9% included a range (e.g., 2–4 tablets) rather
than a specific amount to take (e.g., 3 tablets). Further, there were no clear directions on
when to use and how and when to discontinue use. The vast majority (98.1%) instructed
children with pain to take “as needed” rather than including specific instructions on when
pediatric POs should be taken or in what situations/circumstances the pediatric patient
and/or parent should consider the pediatric PO as being medically “needed”. Most (98.9%)
pediatric PO instructions did not contain directions regarding when to discontinue or wean
off of the pediatric PO, and among the minority of instructions that mentioned weaning
(n = 142), only 68 (0.5%) included specific instructions as to how to wean. Only 3.5% included
a maximum total amount of pediatric PO to take, and 3.2% included the maximum duration
the pediatric PO should be taken. Increasing the rate at which prescribers include these
elements might be beneficial for patient and parent understanding of how and when to
safely discontinue. Thus, these data indicate that major areas of improvement include
using more specific instructions on the amount of pediatric PO to take, providing clearer
directions on when or in what situations/circumstances to use, and how to wean off of or
discontinue.
Potentially confusing phrasing in pediatric PO instructions were common, with 19.4%
containing medical jargon (e.g., “breakthrough pain”, “when tolerating po only”), requiring
a higher reading level to comprehend (e.g., “anticipatory”, “ameliorate”, “multimodal”), or
for previously unspecified but clearly confusing text (e.g., “for severe pain >8/10”). Zheng
et al. [26] reported that 11.3% of e-prescription directions contained at least one quality
control issue even after being transcribed by pharmacy staff. In line with our findings,
Zheng et al. reported similar variability, complexity, and ambiguity, including instructions
containing abbreviations such as ‘tab’ and ‘po’ (per os). While it is clear that prescribing
physicians are not trying to set the stage for future OUD, the experience of using pediatric
POs even exactly as prescribed can orient the brain and behavior to anxiolytic as well as
pain-reduction effects, which can set the stage for future hazardous PO use [27].
It can be especially challenging for patients to interpret and follow the pediatric PO
instructions when they contain abbreviations or medical jargon, and this may even be more
pronounced for less formally-educated families and/or for families for whom English is
not their first language. The average U.S. adult reads at an eighth-grade level [28]. Given
U.S. adult reading skills, the American Medical Association (AMA) and National Institutes
of Health (NIH) officially advise that patient materials not exceed the sixth-grade reading
level [29,30]. Therefore, removal of medical jargon and creating labels with more simple
and straightforward pediatric PO instructions should aid patients in comprehension and
would not disadvantage those with lower literacy rates [21,31].
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Additionally, contact information for families’ follow-up questions were provided in
fewer than 0.001% of the pediatric PO instructions; this is highly problematic given the need
for additional information/clarification from the prescribing provider. While families may
have this information in other locations (e.g., in printed or electronic patient instructions),
making this information easily accessible may be helpful for increasing patient–provider
communication around pediatric PO use and discontinuation. Similarly, fewer than 0.001%
of pediatric PO labels included instructions on how to dispose of leftover pediatric POs.
In fact, recent findings indicate that nearly half of adolescents who use POs in hazardous
ways receive them from friends and relatives [32], suggesting the importance of reducing
leftover pediatric POs by including clear disposal instructions. Including clear instructions
on how to dispose of leftover pediatric POs can decrease potential availability of pediatric
POs for future hazardous PO use.
Results of analyses indicate that patients 13 years of age and older were more likely
to receive more precise pediatric PO instructions and less likely to receive potentially
confusing instructions than patients younger than age 13. Prior research indicates that 25%
of individuals who were prescribed opioids at 13 years or younger may be at enhanced risk
for transitioning into OUD [1]. Therefore, it may be particularly important to improve the
instructions provided to young patients, particularly those under age 13, to mitigate risk for
hazardous use. Compared with non-surgical departments, surgical departments provided
significantly fewer pediatric PO instructions that contained specific dosing instructions.
However, surgical departments had significantly more instructions that directed patients
to limit their pediatric PO use and contained more context as to what the pediatric PO
should be used for. Despite significant differences, only 12.8% and 7.8% of pediatric PO
instructions provided by surgical and non-surgical departments, respectively, contained directions to limit use, while 16.6% and 20.5% of instructions contained potentially confusing
language. These findings represent several areas for continued improvement in pediatric
PO prescribing practices for providers working with young patients and their families.
Here as well, removal of potentially confusing language in pediatric PO instructions and
providing directions to limit use can aid in patient comprehension and reduce inappropriate
pediatric PO use.
5. Limitations and Future Directions
Our study has numerous strengths, including a careful empirical evaluation. At the
same time, results should be interpreted in light of the following limitations. Because data
were extracted from medical records of pediatric patients who received a pediatric PO,
information about other variables of interest could not be evaluated. For example, future
research may examine whether provider demographics and other patient characteristics
are associated with the quality of written pediatric PO instructions provided, given that
these characteristics can exacerbate problems in patient–provider interactions, quality of
care, treatment adherence, and continuity of care [33]. Further, future research may also
examine how differences in prescribing practices may contribute to these differences and
other PO-related health disparities. Due to a low percentage (<20%) of prescriptions having
an associated diagnosis in our data, we were also unable to look at the diagnoses for
which these prescriptions were received. Future studies could identify these by linking
prescription data to encounter data.
6. Conclusions
Addressing the ambiguity, technicality, and variability of pediatric PO label instructions is among one of the most actionable avenues to improve comprehension around
safe pediatric PO use by young people and their families. Increased efforts to develop
structured systems or tools to help standardize label directions, such as embedding a
comprehensive set of direction components into the electronic health record, could improve
the quality of these directions and potentially increase appropriate pediatric PO use by
patients [26]. In addition to producing clearer directions, instructions should be provided
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at an appropriate reading level without medical jargon and abbreviations as well as contain
contact information for follow-up questions, specific weaning and termination directions,
and steps to dispose of unused pediatric POs.
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